Skip to main content
Virax Biolabs Group Ltd logo

Virax Biolabs Group Ltd - Investor Relations & Filings

Listed IPO Jul 2022
Ticker · VRAX ISIN · KYG9470A1094 US Professional, scientific and technical activities
Open in API
Filings indexed 138 across all filing types
Latest filing 2025-12-18 Regulatory Filings
Country US United States of America
Listing US VRAX

About Virax Biolabs Group Ltd

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd. is an innovative biotechnology company specializing in the detection of immune responses and the diagnosis of viral diseases. The company's core activities center on T-cell diagnostics and comprehensive immune profiling, which provide critical insights into disease mechanisms and support the development of novel therapeutic strategies. Its primary technology is the ViraxImmune™ platform, a versatile In-Vitro Diagnostic (IVD) tool applicable across various conditions. Virax Biolabs also employs advanced research tools such as ELISpot assays, a highly sensitive and specific technique for monitoring T-cell activity. Through these offerings, the company aims to accelerate the development of more effective vaccines and contribute to global health.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-12-18 English
6-K
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Virax Biolabs Group Limited, with the SEC. It details the entry into a material agreement involving a private placement offering and issuance of warrants and options, including descriptions of the securities purchase agreement, registration rights agreement, and related terms. The document focuses on financing activities, specifically a private placement and issuance of equity-linked securities, with detailed terms and conditions. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. The primary content is about capital raising and securities issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (8550 characters) and detailed content support this classification with high confidence.
2025-12-04 English
6-K
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Virax Biolabs Group Limited, pursuant to SEC rules. It contains unaudited interim financial statements as of September 30, 2025, and Management's Discussion and Analysis (MD&A) of financial condition and results of operations. The presence of interim financial statements and MD&A indicates this is a comprehensive financial report for a period shorter than a full fiscal year. The document length is 2181 characters, which is relatively short but includes actual financial data and MD&A, not just an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2026
2025-12-02 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-29 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-29 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-10-29 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.